Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00229125
Status:
COMPLETED
Last Update Posted:
2005-09-29
First Post:
2005-09-27
Brief Title:
Comparing the Treatment of Alcohol Withdrawal Syndrome Using Gabapentin Versus Lorazepam
Sponsor:
National Institute on Alcohol Abuse and Alcoholism NIAAA
Organization:
National Institute on Alcohol Abuse and Alcoholism NIAAA
Study Overview
Official Title:
Gabapentin Vs Lorazepam in Alcohol Withdrawal
Status:
COMPLETED
Status Verified Date:
2005-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to evaluate if the medication Gabapentin which is not approved for the treatment of alcohol withdrawal is effective in the treatment of alcohol withdrawal syndrome compared to treatment with Lorazepam
Detailed Description:
In the current protocol we evaluated a newer generation anticonvulsant agent gabapentin Gabapentin does not significantly interact with alcohol or other medications has no abuse potential and is excreted by the kidneys and not the liver
The primary aim of the present application was to evaluate the efficacy of gabapentin in comparison to lorazepam as a benzodiazepine gold standard for the acute outpatient treatment of alcohol withdrawal AW In addition evaluation of the lorazepam rebound effects observed during the current funding period will be replicated and compared with the response to gabapentin Also the acoustic startle response was used to evaluate the neurobiological effects of the medications on underlying AW-related CNS excitation both during and immediately after AW In addition the effect of a history of multiple detoxifications on parameters such as withdrawal symptoms CNS excitability relapse to alcohol use craving for alcohol and response to medication treatment was explored
The primary aim of the present application was to evaluate the efficacy of gabapentin in comparison to lorazepam as a benzodiazepine gold standard for the acute outpatient treatment of alcohol withdrawal AW In addition evaluation of the lorazepam rebound effects observed during the current funding period will be replicated and compared with the response to gabapentin Also the acoustic startle response was used to evaluate the neurobiological effects of the medications on underlying AW-related CNS excitation both during and immediately after AW In addition the effect of a history of multiple detoxifications on parameters such as withdrawal symptoms CNS excitability relapse to alcohol use craving for alcohol and response to medication treatment was explored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIH P-50-AA010761 | None | None | None |